Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: a Children’s Oncology Group phase II study

Lignende værker

• In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model
  af: Morris, Zachary S, et al.
  Udgivet: (2014)
• Randomised Phase II Trial of Irinotecan/Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab (DIN) in Children with Refractory or Relapsed Neuroblastoma: A Report from The Children’s Oncology Group (COG)
  af: Mody, Rajen, et al.
  Udgivet: (2017)
• Genotypes of NK cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy: A Children’s Oncology Group Report
  af: Delgado, DC, et al.
  Udgivet: (2010)
• A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
  af: Ozkaynak, M. Fevzi, et al.
  Udgivet: (2018)
• Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
  af: Ozkaynak, M. Fevzi, et al.
  Udgivet: (2018)